Thrombosis
From the Journals
Surgical LAA occlusion tops anticoagulation for AF thromboprotection
Same protection, less bleeding.
News
FDA surveillance shows how rivaroxaban compares to warfarin
The US Food and Drug Administration’s (FDA) Mini-Sentinel surveillance system has revealed no new safety concerns associated with rivaroxaban use...
From the Journals
Thrombosis risk is elevated with myeloproliferative neoplasms
Diagnosis appears to be the time with greatest risk.
News
EC approves product to treat hemophilia A
The European Commission (EC) has granted marketing authorization for rurioctocog alfa pegol (Adynovi). Rurioctocog alfa pegol (formerly BAX 855)...
Conference Coverage
VIDEO: Anticoagulant underprescribing common, jeopardizing atrial fib patients
Drug-prescribing data show many patients with atrial fibrillation are underdosed with anticoagulants, often due to fears about bleeding.
News
Emicizumab still available despite legal issues
The Roche Group has issued a statement reassuring the US hemophilia community that legal issues are not affecting patient access to emicizumab (...
Conference Coverage
Update of gene therapy in hemophilia A
ATLANTA—Updated trial results have shown that gene therapy can increase factor VIII (FVIII) levels and reduce the need for FVIII infusions in...
Conference Coverage
Caplacizumab improves outcomes in aTTP
ATLANTA—Caplacizumab can improve outcomes in patients with acquired thrombotic thrombocytopenic purpura (aTTP), according to research presented at...
Conference Coverage
HERCULES: Caplacizumab improved platelet response in aTTP
ATLANTA - Caplacizumab led to significantly faster platelet normalization and lower recurrence rates in acquired thrombotic thrombocytopenic...
Conference Coverage
Edoxaban noninferior to dalteparin for VTE in cancer
ATLANTA—Edoxaban is noninferior to dalteparin for the treatment of cancer-associated venous thromboembolism (VTE), a phase 3 study suggests. In...
News
FDA lifts clinical hold on fitusiran trials
The US Food and Drug Administration (FDA) has lifted the hold on clinical trials of fitusiran, an RNAi therapeutic being developed to treat...